

specific since under similar conditions, endostatin did not bind significantly to an epithelial tumor cell line, which is also used in tumor growth inhibition studies.

In the Claims

Please substitute the claim set in the appendix entitled "Clean Version of Pending Claims" for the previously pending claim set. Specific amendments to individual claims are detailed in the following marked up set of claims.

Please amend the claims as follows:

3. (Amended) The composition of claim 2 wherein the targeting moiety comprises RGD, NGR, RGDNGR (SEQ ID NO:8), or NGRRGD (SEQ ID NO:9).
31. (Amended) The method of claim 18 or 21 wherein the targeting moiety is RGD, NGR, RGDNGR (SEQ ID NO:8), or NGRRGD (SEQ ID NO:9).

Remarks

Claims 3 and 31 are amended. Claims 1-26 are pending.

This Preliminary Amendment and the above-referenced SEQUENCE LISTING are filed to conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821 - 1.825. To conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821 through 1.825, a paper copy of a Sequence Listing is submitted herewith. The paper copy of the Sequence Listing in this application is identical to the computer readable form of the Sequence Listing filed in application Serial No. 09/825,129, filed April 03, 2001. In accordance with 37 C.F.R. § 1.821(e), please use the computer readable form filed on November 26, 2001 in application Serial No. 09/825,129 as the computer readable form for the instant application.